Last updated: 2026-11-13 13:13:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Taysha Gene Therapies, Inc. (TSHA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $4.24, with a market capitalization of $1.37B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.46 to $7.30. This page covers its latest market performance, valuation, price trends and company information.
$1.37B | |
$4.24 | |
$4.24 | |
$4.24 | |
$4.21 | |
2.00 | |
3.58M | |
-- | |
$7.30 | |
$3.46 | |
-- | |
-- |
Taysha Gene Therapies, Inc. (TSHA) is trading at $4.24 in pre-market trading as of 2026-11-13 09:30:00, up 0.71% ($0.03) from the previous close of $4.21
Pre-market trading shows how investors are pricing TSHA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Taysha Gene Therapies, Inc. (TSHA) moved from $4.09 to $4.24, representing a gain of 3.67% ($0.15).
The stock traded between $4.00 and $4.53 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 3.05 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 20.4%
TSHA is currently trading at $4.24, placing it 20.4% of the way from its 52-week low of $3.46 to its 52-week high of $7.30. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 99 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Taysha Gene Therapies, Inc. and TSHA stock.
Taysha Gene Therapies (NASDAQ:TSHA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by
Eligible investors can buy real shares of Taysha Gene Therapies, Inc. (TSHA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to TSHA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between TSHA shares and USD.
TSHA Shares to USD
1.00 TSHA shares = 4.24 USD
Calculations are estimates based on the latest available price and are for reference only.
